Panmure Gordon reaffirmed their buy rating on shares of Vernalis plc (LON:VER) in a research note issued to investors on Thursday morning. They currently have a GBX 76 ($0.99) price objective on the stock.
Other equities analysts have also recently issued reports about the stock. Shore Capital restated a house stock rating on shares of Vernalis plc in a report on Tuesday, July 19th. Stifel Nicolaus restated a buy rating and set a GBX 94 ($1.23) price target on shares of Vernalis plc in a report on Friday, July 8th. Finally, Canaccord Genuity restated a buy rating and set a GBX 84 ($1.10) price target on shares of Vernalis plc in a report on Tuesday, July 19th. Four research analysts have rated the stock with a buy rating, Vernalis plc currently has an average rating of Buy and a consensus target price of GBX 80.20 ($1.05).
Shares of Vernalis plc (LON:VER) opened at 44.00 on Thursday. The stock’s market capitalization is GBX 195.85 million. The stock’s 50 day moving average price is GBX 43.84 and its 200-day moving average price is GBX 45.97. Vernalis plc has a 12 month low of GBX 31.00 and a 12 month high of GBX 84.02.
About Vernalis plc
Vernalis plc is a commercial-stage pharmaceutical holding company. The Company is engaged in the research, development and commercialization of pharmaceutical products for a range of medical disorders. The Company has two marketed products: Tuzistra XR in the United States prescription cough cold market, and frovatriptan, an acute treatment for migraine.
Receive News & Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related companies with MarketBeat.com's FREE daily email newsletter.